The Netherlands Translational Research Center (NTRC) has identified IDO1 inhibitors with best-in-class properties

News
10 December 2015

They have been developed from a series of inhibitor compounds first identified by screening the JECL of the European Lead Factory against IOD1 and TDO, important targets in cancer immunotherapy.

Read the press release.